• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philochem will be attending the 10th World ADC Conference in London

by last | Nov 13, 2022 | 2020, Press Releases

Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small Molecule-DrugConjugates: Getting small to enhance targeting” Jacopo Millul...

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

by Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors.   The...

Philogen publishes a new study on OncoFAP in Clinical Cancer Research

by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific

The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...

Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.

by Lisa Nadal | Sep 15, 2022 | 2022, Press Releases, Scientific

The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

by m.romi | Jul 25, 2022 | 2022, Press Releases, Scientific

More details

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

by mfantozzi | Feb 17, 2022 | 2022, Press Releases, Scientific

More details
« Older Entries

Recent Posts

  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
  • Philochem will be attending the 10th World ADC Conference in London
  • Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
  • Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch